Northwest Bank & Trust Co Makes New Investment in Johnson & Johnson (NYSE:JNJ)

Northwest Bank & Trust Co acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,420 shares of the company’s stock, valued at approximately $223,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. 4J Wealth Management LLC grew its position in Johnson & Johnson by 2.2% during the 4th quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock valued at $444,000 after purchasing an additional 62 shares during the last quarter. My Personal CFO LLC lifted its stake in Johnson & Johnson by 1.4% during the 4th quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock valued at $713,000 after acquiring an additional 62 shares during the period. Eagle Strategies LLC lifted its stake in shares of Johnson & Johnson by 1.8% in the 4th quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after purchasing an additional 63 shares during the period. Clearview Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after purchasing an additional 64 shares during the period. Finally, Brookmont Capital Management lifted its stake in shares of Johnson & Johnson by 0.4% in the 4th quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock worth $2,328,000 after purchasing an additional 64 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, May 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Tuesday, June 4th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Monday, June 10th. Morgan Stanley cut their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $174.07.

Johnson & Johnson Stock Up 0.1 %

Shares of JNJ stock traded up $0.09 on Friday, hitting $145.54. The stock had a trading volume of 4,075,342 shares, compared to its average volume of 7,121,075. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The business has a 50 day moving average price of $148.38 and a 200 day moving average price of $154.69. The company has a market cap of $350.27 billion, a PE ratio of 9.07, a P/E/G ratio of 2.42 and a beta of 0.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the firm earned $2.68 earnings per share. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s payout ratio is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.